Tigecycline activity: Low resistance rates but problematic disc breakpoints revealed by a multicentre sentinel survey in the UK

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 12, 2010, Pages 2602-2609

  Hope, R ^a   Mushtaq, S ^a   James, D ^a   Pllana, T ^a   Warner, M ^a   Livermore, D M ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Agar dilution; BSAC; TEST

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CIPROFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GENTAMICIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ADOLESCENT; ADULT; AGAR DILUTION; AGED; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATE; COAGULASE NEGATIVE STAPHYLOCOCCUS; ENTEROBACTER; ENTEROCOCCUS; ESCHERICHIA COLI; FECES CULTURE; FEMALE; GRAM NEGATIVE AEROBIC RODS AND COCCI; HUMAN; KLEBSIELLA; MALE; NONHUMAN; PROTEUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; UNITED KINGDOM; URINE CULTURE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; GREAT BRITAIN; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; SENTINEL SURVEILLANCE;

EID: 78149472946     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq370     Document Type: Article

References (22)

1. Petersen PJ, Jacobus NV, Weiss WJ et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43: 738-44.
2. Fluit AC, Florijn A, Verhoef J et al. Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline. Antimicrob Agents Chemother 2005; 49: 1636-8.
3. Hirata T, Saito A, Nishino K et al. Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936). Antimicrob Agents Chemother 2004; 48: 2179-84.
4. Woodford N, Ellington MJ, Coelho JM et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents 2006; 27: 351-3.
5. BSAC Resistance Surveillance Project. http://www.bsacsurv.org (21 July 2009, date last accessed).
6. Department of Health's mandatory MRSA reporting scheme, Health Protection Agency. http://www.hpa.org.uk/infections/topics_az/staphylo/staphylo_mandatory_surveillance.htm (8 August 2010, date last accessed).
7. Reacher MH, Shah A, Livermore DM et al. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. BMJ 2000; 320: 213-6.
8. European Antimicrobial Resistance Surveillance System (EARSS). http://www.earss.rivm.nl (8 August 2010, date last accessed).
9. Andrews JM for the BSAC Working Party on Susceptibility Testing. BSAC standardized disc susceptibility testing method (version 6). J Antimicrob Chemother 2007; 60: 20-41.
10. Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Chemother 2001; 48 Suppl 1: 5-16.
11. Andrews JM for the BSAC Working Party on Susceptibility Testing. BSAC standardized disc susceptibility testing method (version 8). J Antimicrob Chemother 2009; 64: 454-89.
12. Clinical and Laboratory Standards Institute. Development of in Vitro Susceptibility Testing Criteria and Quality Control Parameters-Third Edition: Approved Guideline M23-A3. CLSI, Wayne, PA, USA, 2008.
13. MacGowan AP, Wise R. Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J Antimicrob Chemother 2001; 48 Suppl 1: 17-28.
14. Hope R, Parsons T, Mushtaq S et al. Determination of disc breakpoints and evaluation of Etests for tigecycline susceptibility testing by the BSAC method. J Antimicrob Chemother 2007; 60: 770-4.
15. Andrews JM for the BSAC Working Party on Susceptibility Testing. BSAC standardized disc susceptibility testing method (version 7). J Antimicrob Chemother 2008; 62: 256-78.
16. Nørskov-Lauritsen N, Marchandin H, Dowzicky MJ. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007). Int J Antimicrob Agents 2009; 34: 121-30.
17. Dowzicky MJ, Park CH. Update on antimicrobial susceptibility rates among Gram-negative and Gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007. Clin Ther 2008; 30: 2040-50.
18. Garrison MW, Mutters R, Dowzicky MJ. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: Tigecycline Evaluation and Surveillance Trial 2004 to 2007. Diagn Microbiol Infect Dis 2009; 65: 288-99.
19. Bouchillon SK, Iredell JR, Barkham T et al. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST). Int J Antimicrob Agents 2009; 33: 130-6.
20. BSACwebsite. http://www.bsac.org.uk (8 August 2010, date last accessed).
21. BSAC standardized disc susceptibility testing method (version 6.1). http://www.bsac.org.uk/_db/_documents/version_6.1.pdf (15 December 2007, date last accessed).
22. Tigecycline Evaluation and Surveillance Trial (TEST). http://www.testsurveillance.com (8 August 2010, date last accessed).